Cimzia (certolizumab pegol) / Astellas, UCB 
Welcome,         Profile    Billing    Logout  
 50 Diseases   29 Trials   29 Trials   3299 News 


12345678910111213...3839»
  • ||||||||||  Review, Journal:  Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges. (Pubmed Central) -  Jan 31, 2025   
    Conversely, while newly approved HS medications such as secukinumab and bimekizumab show promise for the general population, further research is necessary to evaluate their safety profiles in pregnant and breastfeeding individuals. The scant research available on HS in pregnant and lactating women, also shown by our systematic literature review, highlights the need for a comprehensive investigation into the safety, efficacy, and suitability of management strategies.
  • ||||||||||  Review, Journal:  Management of Anal Fistula with Crohn's Disease. (Pubmed Central) -  Jan 30, 2025   
    (certolizumab pegol), anti-interleukin-12/23 (ustekinumab), and anti-?4?7 integrin antibodies (vedolizumab) were evaluated...In addition to biologics, molecular target drugs and even regenerative medicine using mesenchymal stem cells have been introduced to further expand the treatment options for consideration by medical personnel. We herein discuss the management of PFCD by focusing on studies conducted in the United States and Europe where researchers used recommended guidelines and consensus statements to evaluate the efficacy of each medication and published their findings in peer-reviewed journals.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Enrollment closed, Trial completion date, Trial primary completion date:  OTIS Cimzia Pregnancy Registry (clinicaltrials.gov) -  Jan 28, 2025   
    P=N/A,  N=925, Active, not recruiting, 
    We herein discuss the management of PFCD by focusing on studies conducted in the United States and Europe where researchers used recommended guidelines and consensus statements to evaluate the efficacy of each medication and published their findings in peer-reviewed journals. Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Mar 2026 | Trial primary completion date: Sep 2023 --> Jan 2026
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Journal:  Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report. (Pubmed Central) -  Jan 13, 2025   
    inhibitor that lacks the fragment crystallizable region preventing active placental transfer and could be used in pregnancy and lactation if clinically needed and is label for chronic plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease. Herein, we describe a case of a 32-year-old pregnant woman with Hurley stage III hidradenitis suppurativa successfully treated with certolizumab pegol.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Journal:  What is Rheumatoid factor-from screening to personalized management. (Pubmed Central) -  Jan 12, 2025   
    Meanwhile, certolizumab pegol (CZP), a TNF inhibitor without the Fc region, remains at high concentrations in the blood...When serum IgM-RF levels are high, antibody drugs with the Fc region are more likely to bind to IgM-RF and be degraded. Thus, CZP without the Fc region may be more favorable for patients with high serum RF levels.
  • ||||||||||  Opdivo (nivolumab) / BMS, Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion date, Trial primary completion date:  Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery (clinicaltrials.gov) -  Nov 19, 2024   
    P2,  N=60, Recruiting, 
    The findings of this population PK analysis support the maintenance of established certolizumab pegol dosing regimens throughout pregnancy. Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
  • ||||||||||  Rinvoq (upadacitinib) / AbbVie
    Upadacitinib exposure during pregnancy in seronegative Rheumatoid arthritis () -  Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_12;    
    Moreover, ACPA, RF and SE allele-related genotypes were not, alone or in combination, associated with clinical responses of importance sufficiently strongly to warrant implementation in clinical practice. She has no history of spontaneous abortions.At the time of her RA diagnosis, the patient was considering pregnancy and was initially started on sulfasalazine...Despite this treatment, she exhibited only a partial response with ongoing disease activity, leading to a change to etanercept in August 2021.When etanercept proved ineffective, adalimumab was considered in January 2022...She was subsequently started on certolizumab...Access to a medical obstetrician team is invaluable in managing such cases.
  • ||||||||||  Siliq (brodalumab) / Bausch Health, Humira (adalimumab) / AbbVie
    Induction Cost Per Responder of Brodalumab Compared With Other Biologic Therapies for Patients With Moderate to Severe Plaque Psoriasis in Canada () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_3175;    
    The CPR was estimated as the drug acquisition costs during the induction period multiplied by the number needed to treat (NNT) for achieving PASI 75, 90, or 100 for the following treatments: adalimumab (innovator and SEB), brodalumab, bimekizumab, certolizumab pegol, etanercept (innovator and SEB), guselkumab, infliximab (innovator and SEB), ixekizumab, risankizumab, secukinumab, tildrakizumab, ustekinumab (innovator and SEB). These results demonstrate that brodalumab has the lowest induction CPR across all PASI outcomes compared to other biologic therapies, including SEB therapies, thus providing the best value for money for patients, prescribers, and payers.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Cosentyx (secukinumab) / Novartis, Cimzia (certolizumab pegol) / Astellas, UCB
    Cost of Biologics in Patients Suffering From Psoriasis in Greece: A Retrospective Longitudinal Cohort Study () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1158;    
    The study highlights significant variability in biologic treatment costs for PsO, influenced by drug, persistence, and prior treatment history. These findings underscore the importance of balancing clinical efficacy and economic impact in treatment decisions for PsO, ensuring effective care while managing healthcare resources efficiently.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Facial Hyperpigmentation Following Adalimumab. (Pubmed Central) -  Nov 1, 2024   
    inhibitors. Clinicians should consider this potential side effect in patients presenting with hyperpigmentation, and sun protection should be recommended as a preventive measure.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Review, Journal:  Non-Infectious Uveitis and Pregnancy, is There an Optimal Treatment? Uveitis Course and Safety of Uveitis Treatment in Pregnancy. (Pubmed Central) -  Sep 24, 2024   
    Other therapies (such as Methotrexate, Mycophenolate Mofetil and alkylating agents) are teratogenic or have a detrimental effect on the foetus. Furthermore, careful multidisciplinary preconception discussions and close follow-up are recommended, monitoring for flare-ups and actively tapering medication doses, with a primary endpoint focused on protecting ocular tissues from inflammation, whilst giving minimal risk of poor pregnancy and foetal outcomes.
  • ||||||||||  Clinical, Journal:  Comparison table: Some drugs for plaque psoriasis. (Pubmed Central) -  Sep 21, 2024   
    As such, with careful examination of the risks and benefits, there may be a role for rotavirus vaccination in this population. No abstract available
  • ||||||||||  Review, Journal:  Drugs for plaque psoriasis. (Pubmed Central) -  Sep 21, 2024   
    No abstract available No abstract available
  • ||||||||||  Review, Journal:  Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors (Pubmed Central) -  Aug 23, 2024   
    Nevertheless, these therapies are expensive and are associated with potential adverse effects, including increased risk of infections and malignancies. This review discusses the mechanisms, clinical efficacy, safety profiles, and therapeutic positioning of anti-TNF agents in IBD management, integrating current Korean treatment guidelines.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Lymphocytic Esophagitis and Crohn's Disease in Adult (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_2815;    
    She also has chronic GERD managed with Omeprazole...Therefore, the relationship between LyE and CD in adult patients remains unclear, with limited literature available. Reporting more similar cases will help in conducting more studies to assess the association in adults and direct further screening and management.
  • ||||||||||  A Rare Finding of Rectal Squamous Metaplasia in Crohn's Disease (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_1502;    
    He had nonresponse to infliximab, adalimumab, certolizumab, and azathioprine...He was started on vedolizumab and budesonide and went into clinical remission...Although there are no guidelines for HPV prophylaxis in IBD for SCC, HPV vaccination should be recommended in patients < 45 years old for prevention of anal SCC in high-risk patients, including those with rectal squamous metaplasia. Figure: A. Salmon colored rectal mucosa B. Hypopigmented region extending to anus
  • ||||||||||  At a Crossroad of Chronicity: Crohn's Disease and Endometriosis (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_1475;    
    Due to this, she was started on Risankizumab induction and maintenance in early 2023...Endometriosis rarely involves the mucosa layers of the bowel, which precludes direct endoscopic visualization. This case demonstrates a rare co-existence of poorly controlled CD and bowel endometriosis presenting with small bowel obstructive.
  • ||||||||||  tofacitinib / Generic mfg.
    A case of cutaneous and osteosarcoidosis successfully treated with Tofacitinib (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_5126;    
    JAK proteins are associated with cell surface cytokine receptors, and so are early mediators of cell response to inflammation whereby STAT driven transcription is initiated. In sarcoidosis, it is predominantly Type 1 inflammatory cytokines and interferon gamma that bind to JAK associated cytokine receptors1.